前蛋白转化酶枯草杆菌蛋白酶Kexin-9抑制剂在降脂治疗中的研究进展

Research progress of proprotein convertase subtilin Kexin-9 inhibitor in lipid-lowering therapy

前蛋白转化酶枯草杆菌蛋白酶Kexin-9(PCSK9)已成为调节低密度脂蛋白胆固醇(LDL-C)水平的重要靶点,PCSK9抑制剂能显著降低血浆LDL-C水平,他汀类药物也可降低LDL-C水平但会导致PCSK9水平升高。临床试验已证实他汀类药物与PCSK9抑制剂联合使用的疗效和安全性。尽管不同类型的PCSK9抑制剂作用方式不同,但其在患者中发挥的效果是一致的,目前仍在进行的临床试验将进一步证明其安全性和降低心血管风险的作用。

Proprotein convertase subtilisin Kexin type 9(PCSK9)has become an essential target for regulating low-density lipoprotein cholesterol(LDL-C)level.PCSK9 inhibitors significantly reduces plasma LDL-C level,Statins also reduces LDL-C level but raises PCSK9 level.A quantity of clinical trials has verified the efficacy and safety of Statins in combination with PCSK9 inhibitors.Although different types of PCSK9 inhibitor act in varying ways,their effects are the same in different patients,and the ongoing clinical trials will further demonstrate their safety and role in reducing cardiovascular risk.